Radioimmunotherapy with engineered antibodies

Expert Opinion on Biological Therapy

Volumn 4, Issue 2, 2004, Pages 217-231

  Russeva, Maria G ^a   Adams, Gregory P ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Cancer therapy; Chimaeric; Diabody; Humanised; Monoclonal antibody; Radioimmunotherapy; Radioisotope; Single chain Fv

Indexed keywords

ANTIBODY; CHIMERIC ANTIBODY; IMMUNOGLOBULIN F(AB) FRAGMENT; MONOCLONAL ANTIBODY; RADIOISOTOPE;

ANTIBODY ENGINEERING; CANCER THERAPY; MOLECULAR BIOLOGY; RADIOIMMUNOTHERAPY; REVIEW; TARGET ORGAN;

ANTIBODIES; ANTIBODIES, MONOCLONAL; HUMANS; PROTEIN ENGINEERING; RADIOIMMUNOTHERAPY; RADIOISOTOPES; RECOMBINANT FUSION PROTEINS;

EID: 1042276824     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.4.2.217     Document Type: Review

References (85)

1. KOHLER G, MILSTEIN C: Continuous cultures of fused cells secreting antibody of predefined specificity. Nature (1975) 256:495-497.
2. HOLECHEK MJ: Glomerular filtration: an overview. Nephrol. Nurs. J. (2003) 30:285-290; quiz 291-282.
3. SCHIER R, MCCALL A, ADAMS GP et al.: Isolation of picomolar affinity anti-c-erbB-2 single-chain Fv by molecular evolution of the complementarity determining regions in the center of the antibody binding site. J. Mol. Biol. (1996) 263:551-567.
4. SCHIER R, BYE J, APELL G et al.: Isolation of high-affinity monomeric human anti-c-erbB-2 single chain Fv using affinity-driven selection. J. Mol. Biol. (1996) 255:28-43.
5. GHETIE V, WARD ES: Multiple roles for the major histocompatibility complex class I-related receptor FcRn. Am. Rev. Immunol. (2000) 18:739-766.
6. BOULIANNE GL, HOZUMI N, SHULMAN MJ: Production of functional chimaeric mouse/human antibody. Nature (1984) 312:643-646.
7. MORRISON SL, JOHNSON MJ, HERZENBERG LA, OI VT: Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. Prac. Natl. Acad. Sci. USA (1984) 81:6851-6855.
8. JONES PT, DEAR PH, FOOTE J, NEUBERGER MS, WINTER G: Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature (1986) 321:522-525.
9. KORTT AA, LAH M, ODDIE GW et al.: Single-chain Fv fragments of anti-neuraminidase antibody NC10 containing five- and ten-residue linkers form dimers and with zero-residue linker a trimer. Protein Eng. (1997) 10:423-433.
10. HUSTON JS, LEVINSON D, MUDGETT-HUNTER M et al.: Protein engineering of antibody binding sites: recovery of specific activity in an antidigoxin single-chain Fv analogue produced in Escherichia coli. Proc. Natl. Acad. Sci. USA (1988) 85:5879-5883.
11. BIRD RE, HARDMAN KD, JACOBSON JW et al.: Single-chain antigen-binding proteins. Science (1988) 242:423-426.
12. MARKS JD, HOOGENBOOM HR, BONNERT TP, MCCAFFERTY J, GRIFFITHS AD, WINTER G: By-passing immunization. Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol. (1991) 222:581-597.
13. ADAMS GP, MCCARTNEY JE, TAI MS et al.: Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. Cancer Res. (1993) 53:4026-4034.
14. BERESFORD GW, PAVLINKOVA G, BOOTH BJ, BATRA SK, COLCHER D: Binding characteristics and tumor targeting of a covalently linked divalent CC49 single-chain antibody. Int. J. Cancer (1999) 81:911-917.
15. ADAMS GP, ROBINSON MK, HORAK E et al.: Anti-HER2/HER3 bispecific single-chain Fv molecules for cancer detection and therapy. Proc. Am. Assoc. Cancer Res. (2003) 44:1327 (Abstract #R5784).
16. WU AM, YAZAKI PJ: Designer genes: recombinant antibody fragments for biological imaging. QJ. Nucl. Med. (2000) 44:268-283.
17. LU D, SHEN J, VIL MD et al.: Tailoring in vitro selection for a picomolar-affinity human antibody directed against VEGF receptor 2 for enhanced neutralizing activity. J. Biol. Chem. (2003) 278(44):43496-43507.
18. DAVIES CDE L, BERK DA, PLUEN A, JAIN RK: Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br. J. Cancer (2002) 86:1639-1644.
19. HALIN C, NIESNE RU, VILLANI ME, ZARDI L, NERI D: Tumor-targeting properties of antibody-vascular endothelial growth factor fusion proteins. Int. J. Cancer (2002) 102:109-116.
20. CARNEMOLLA B, BORSI L, BALZA E et al.: Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 99:1659-1665.
21. HALIN C, GAFNER V, VILLANI ME et al.: Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res. (2003) 63:3202-3210.
22. SMALLSHAW JE, GHETIE V, RIZO J et al.: Genetic engineering of an immunotoxin to eliminate pulmonary vascular leak in mice. Nat. Biotechnol. (2003) 21:387-391. Identifies toxin sequences associated with VLS - these sequences could be used to enhance extravasation of mAbs.
23. WOCHNER RD, STROBER W, WALDMANN TA. The role of the kidney in the catabolism of Bence Jones proteins and immunoglobulin fragments. J. Exp. Med. (1967) 126:207-221.
24. LEONG SR, DEFORGE L, PRESTA L et al.: Adapting pharmacokinetic properties of a humanized anti-interleukin-8 antibody for therapeutic applications using site-specific pegylation. Cytokine (2001) 16:106-119.
25. LU ZR, SHIAH JG, KOPECKOVA P, KOPECEK J: Preparation and biological evaluation of polymerizable antibody Fab' fragment targeted polymeric drug delivery system. J. Control. Release (2001) 74:263-268.
26. DENNIS MS, ZHANG M, MENG YG et al.: Albumin binding as a general strategy for improving the pharmacokinetics of proteins. J. Biol. Chem. (2002) 277:35035-35043. Engineering albumin binding sites into antibody fragments to prolong serum half-life.
27. ADAMS GP, SHALLER C, GARMESTANI K, TESFAYE A, WALDMANN TA, BRECHBIEL MW: Alpha-emitting radioisotopes conjugated to anti-HER2/neu diabodies for the radioimmunotherapy of solid tumors. Paper presented at the American Chemical Society. Division of Nuclear Chemistry and Technology. New Orleans, LA, USA (2003).
28. BEHR TM, SHARKEY RM, JUWEID ME et al.: Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. Cancer Res. (1995) 55:3825-3834.
29. 90Y-labeled CO17-1A Fab' fragments in a human colonic cancer model. Cancer Res. (1999) 59:2635-2643.
30. TARBURTON JP, HALPERN SE, HAGAN PL et al.: Effect of acetylation on monoclonal antibody ZCE-025 Fab': distribution in normal and bearing-bearing mice. J. Biol. Response Mod. (1990) 9:221-230.
31. PAVLINKOVA G, BERESFORD G, BOOTH BJ, BATRA SK, COLCHER D: Charge-modified single chain antibody constructs of monoclonal antibody CC49: generation, characterization, pharmacokinetics, and biodistribution analysis. Nucl. Med. Biol. (1999) 26:27-34.
32. HOWELL RW, RAO DV, SASTRY KS: Macroscopic dosimetry for radioimmunotherapy: nonuniform activity distributions in solid tumors. Med. Phys. (1989) 16:66-74.
33. HUMM JL, COBB LM: Nonuniformity of tumour dose in radioimmunotherapy. J. Nucl. Med. (1990) 31:75-83.
34. NIKJOO H, O'NEILL P, WILSON WE, GOODHEAD DT: Computational approach for determining the spectrum of DNA damage induced by ionizing radiation. Radiat. Res. (2001) 156:577-583.
35. 2 fragments with the alpha-particle-emitting nuclide Astatine-211: preservation of immunoreactivity and in vivo localizing capacity. Proc. Natl. Acad. Sci. USA (1989) 86:7149-7153.
36. ADAMS GP, SHALLER CC, CHAPPELL LL et al.: Delivery of the alpha-emitting radioisotope Bismuth-213 to solid tumors via single-chain Fv and diabody molecules. Nucl. Med. Biol. (2000) 27:339-346.
37. MCDEVITT MR, MA D, LAI LT et al.: Tumour therapy with targeted atomic nanogenerators. Science (2001) 294:1537-1540.
38. WISEMAN GA, LEIGH B, ERWIN WD et al.: Radiation dosimetry results for Zevalin radioimmunotherapy of rituximab-refractory non-Hodgkin lymphoma. Cancer (2002) 94:1349-1357.
39. WILLIAMS LE, LIU A WU AM et al.: Figures of merit (FOMs) for imaging and therapy using monoclonal antibodies. Med. Phys. (1995) 22:2025-2027.
40. STEIN R, GOVINDAN SV, MATTES MJ et al.: Improved iodine radiolabels for monoclonal antibody therapy. Cancer Res. (2003) 63:111-118. Indirect radioiodination strategy to decrease dehalogenation.
41. ALCINDOR T, WITZIG TE: Radioimmunotherapy with Yttrium-90 ibritumomab tiuxetan for patients with relapsed CD20+ B-cell non-Hodgkin's lymphoma. Curr. Treat. Options Oncol. (2002) 3:275-282.
42. LEONARD JP, SIEGEL JA, GOLDSMITH SJ: Comparative physical and pharmacologic characteristics of Iodine-131 and Yttrium-90: implications for radioimmunotherapy for patients with non-Hodgkin's lymphoma. Cancer Invest. (2003) 21:241-252.
43. PRESS OW, RASEY J: Principles of radioimmunotherapy for hematologists and oncologists. Semin. Oncol. (2000) 27:62-73.
44. 131I-counterpart. Ann. Nucl. Med. (2001) 15:199-202.
45. ADAMS GP, SCHIER R, MCCALL AM et al.: High affinity restricts the localization and tumour penetrarion of single-chain fv antibody molecules. Cancer Res. (2001) 61:4750-4755. Extremely high affinity limits tumour penetration of antibody fragments.
46. GRAFF CP, WITTRUP KD: Theoretical analysis of antibody targeting of tumour spheroids: importance of dosage for penetration, and affinity for retention. Cancer Res. (2003) 63:1288-1296.
47. ADAMS GP, SCHIER R, MCCALL AM et al.: Prolonged in vivo tumour retention of a human diabody targeting the extracellular domain of human HER2/neu. Br. J. Cancer (1998) 77:1405-1412.
48. ADAMS GP: Effective radioimmunotherapy of solid tumors using anti-HER2/neu diabodies conjugated to alpha particle and beta particle emitting radioisotopes. Presented at the Ninth Conference on Cancer Therapy with Antibodies and Immunoconjugates, Princeton, New Jersey, USA. Cancer Biother. Radiopharm. (2002) 17:481.
49. YAZAKI PJ, WU AM, TSAI SW et al.: Tumour targeting of radiometal labelled anti-CEA recombinant T84.66 diabody and t84.66 minibody: comparison to radioiodinated fragments. Bioconjug. Chem. (2001) 12:220-228. Identifies differential normal organ retention patterns for radiometal-labelled diabodies and minibodies.
50. HU S, SHIVELY L, RAUBITSCHEK A et al.: Minibody: a novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res. (1996) 56:3055-3061.
51. GOEL A, COLCHER D, BARANOWSKA-KORTYLEWICZ J et al.: Genetically engineered tetravalent single-chain Fv of the pancarcinoma monoclonal antibody CC49: improved biodistribution and potential for therapeutic application. Cancer Res. (2000) 60:6964-6971.
52. SLAVIN-CHIORINI DC, KASHMIRI SV, SCHLOM J et al.: Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. Cancer Res. (1995) 55:5957s-5967s.
53. SLAVIN-CHIORINI DC, KASHMIRI SV, LEE HS et al.: A CDR-grafted (humanized) domain-deleted antitumor antibody. Cancer Biother. Radiopharm. (1997) 12:305-316.
54. FERRARA N: Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin. Oncol. (2002) 29:10-14.
55. 213Bi]-MAb TES-23. Eur. J. Cancer (2002) 38:1278-1287.
56. 131I-labeled anti-tenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2002) 20:1389-1397.
57. AXWORTHY DB, RENO JM, HYLARIDES MD et al.: Cure of human carcinoma xenografts by a single dose of pretargeted Yttrium-90 with negligible toxicity. Proc. Natl. Acad. Sci. USA (2000) 97:1802-1807.
58. BARBET J, KRAEBER-BODERE F, VUILLEZ JP, GAUTHEROT E, ROUVIER E, CHATAL JF: Pretargeting with the affinity enhancement system for radioimmunotherapy. Cancer Biother. Radiopharm. (1999) 14:153-166. Divalent PRIT ligand enhances binding avidity and increases tumour localisation.
59. CHANG CH, SHARKEY RM, ROSSI EA et al.: Molecular advances in pretargeting radioimmunotherapy with bispecific antibodies. Mol. Cancer Ther. (2002) 1:553-563.
60. SCHULTZ J, LIN Y, SANDERSON J et al.: A tetravalent single-chain antibody-streptavidin fusion protein for pretargeted lymphoma therapy. Cancer Res. (2000) 60:6663-6669.
61. BOERMAN OC, KRANENBORG MH, OOSTERWIJK E et al.: Pretargeting of renal cell carcinoma: improved tumor targeting with a bivalent chelate. Cancer Res. (1999) 59:4400-4405.
62. 90yttrium-DOTA-peptide-ChL6. Prostate (2002) 50:27-37. Effective combination of RAIT with radiosensitising chemotherapeutic agents.
63. KRAEBER-BODERE F, SAI-MAUREL C, CAMPION L et al.: Enhanced antitumor activity of combined pretargeted radioimmunotherapy and paclitaxel in medullary thyroid cancer xenograft. Mol. Cancer Ther. (2002) 1:267-274. Effective combination of PRIT with radiosensitising chemotherapeutic agents.
64. PEDLEY RB, HILL SA, BOXER GM et al.: Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate. Cancer Res. (2001) 61:4716-4722. Demonstrated the complementary nature of RAIT and antivascular agents.
65. KINUYA S, KAWASHIMA A, YOKOYAMA K et al.: Cooperative effect of radioimmunotherapy and antiangiogenic therapy with thalidomide in human cancer xenografts. J. Nucl. Med. (2002) 43:1084-1089.
66. 90Y-conjugated mAb.
67. 131I-conjugated mAb.
68. WHITE CA, WEAVER RL, GRILLO-LOPEZ AJ: Antibody-targeted immunotherapy for treatment of malignancy. Ann. J. Med. (2001) 52:125-145.
69. HAJJAR G, SHARKEY RM, BURTON J et al.: Phase I radioimmunotherapy trial with Iodine-131-labeled humanized MN-14 anti-carcinoembryonic antigen monoclonal antibody in patients with metastatic gastrointestinal and colorectal cancer. Clin. Colorectal Cancer (2002) 2:31-42.
70. 177Lu) in advanced prostate cancer (Pca). Proc. Am. Soc. Clin. Oncol. (2003):401 (Abstract 1612).
71. 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies. Clin. Cancer Res. (2000) 6:3855-3863.
72. BEHR TM, LIERSCH T, GREINER-BECHERT L et al.: Radioimmunotherapy of small-volume disease of metastatic colorectal cancer. Cancer (2002) 94:1373-1381.
73. CASEY JL, NAPIER MP, KING DJ et al.: Tumour targeting of humanised cross-linked divalent-Fab' antibody fragments: a clinical Phase I/II study. Br. J. Cancer (2002) 86:1401-1410.
74. 131I-HuCC49 delta CH2 in patients with metastatic colorectal carcinoma. Proc. Am. Soc. Clin. Oncol. (2003):182 (Abstract 730). First clinical trial of radiolabelled domain-deleted mAb.
75. 123I-labeled 80 kD engineered anti-CEA antibody fragment (cT84.66 Minibody) in patients with colorectal cancer. J. Nucl. Med. Suppl. (2003):402P (Abstract #1433). First clinical trial with radiolabelled minibody.
76. SHEN S, FORERO A, LOBULGIO AF et al.: Patient-specific radiation dosimetry of pretarget radioimmunotherapy using CC-49 fusion protein in patients with gastrointestinal malignancies. J. Nucl. Med. Suppl. (2003):151P (Abstract #494).
77. LEICHNER PK, AKABANI G, COLCHER D et al.: Patient-specific dosimetry of Indium-111- and Yttrium-90-labeled monoclonal antibody CC49. J. Nucl. Med. (1997) 38:512-516.
78. WEIDEN PL, BREITZ HB: Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL). Crit. Rev. Oncol. Hematol. (2001) 40:37-51.
79. HUSTON JS, GEORGE AJ, ADAMS GP et al.: Single-chain Fv radioimmunotargeting. QJ. Nucl. Med. (1996) 40:320-333.
80. 99mTechnetium-labeled single-chain Fv fragments against high molecular weight melanoma-associated antigen. Clin. Cancer Res. (2000) 6:4921-4931.
81. FANG J, JIN HB, SONG JD: Construction, expression and tumor targeting of a single-chain Fv against human colorectal carcinoma. World J. Gastroenterol. (2003) 9:726-730.
82. WEINER LM, HOUSTON LL, HOUSTON JC et al.: Improving the tumor-selective delivery of single-chain Fv molecules. Tumor Target. (1995):51-60.
83. MILENIC DE, YOKOTA T, FILPULA DR et al.: Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. Cancer Res. (1991) 51:6363-6371.
84. SLAVIN-CHIORINI DC, HORAN HAND PH, KASHMIRI SV, CALVO B, ZAREMBA S, SCHLOM J: Biologic properties of a CH2 domain-deleted recombinant immunoglobulin. Int. J. Cancer (1993) 53:97-103.
85. ZWEIT J: Radionuclides and carrier molecules for therapy. Phys. Med. Biol. (1996) 41:1905-1914.